Sofosbuvir and ribavirin with or without pegylated-interferon in hepatitis C virus genotype-2 or -3 infections: A systematic review and meta-analysis

Bayatpoor, Mohammad Ehsan; Khosravi, Mohammad Hossein; Sharafi, Heidar; Rezaee-Zavareh, Mohammad Saeid; Behnava, Bita; Alavian, Seyed Moayed

doi:10.5812/archcid.79465

Article (Scientific journals)

Sofosbuvir and ribavirin with or without pegylated-interferon in hepatitis C virus genotype-2 or -3 infections: A systematic review and meta-analysis

Bayatpoor, Mohammad Ehsan; Khosravi, Mohammad Hossein; Sharafi, Heidar et al.

2019 • In Archives of Clinical Infectious Diseases, 14 (1)

Peer reviewed

Permalink
https://hdl.handle.net/2268/291103

DOI
10.5812/archcid.79465

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Sofosbuvir and Ribavirin with or Without Pegylated-Interferon in Hepatitis C Virus Genotype-2 or -3 Infections A Systematic Review and Meta-Analysis.pdf

Author postprint (1.54 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Hepatitis C; Meta-analysis; Pegylated-interferon; Ribavirin; Sofosbuvir; Microbiology; Immunology and Microbiology (miscellaneous); Toxicology; Critical Care and Intensive Care Medicine; Public Health, Environmental and Occupational Health; Infectious Diseases

Abstract :

[en] Background: Direct-acting antiviral agents (DAAs) have changed the treatment landscape of hepatitis C virus (HCV) infection. Sofosbuvir (SOF), as a DAA inhibiting HCV NS5B polymerase, has found a remarkable contribution to the treatment regimens of HCV genotype-2 (HCV-2) and -3 infections. Objectives: In this meta-analysis, we aimed to evaluate the efficacy of the combination of SOF and Ribavirin (RBV) with or without pegylated-interferon (PegIFN) in the treatment of HCV-2 and -3 infections. Methods: In this meta-analysis, we searched electronic databases including PubMed, Scopus, ScienceDirect, andWeb of Science using appropriate and relevant keywords. Based on the results of the heterogeneity test (chi-squared and I-squared), fixed- or randomeffects models were used to calculate the pooled sustained virological response (SVR) rates. Results: After removing duplicates and screening of 1408 articles, 16 studies were included in the quantitative synthesis. The pooled SVR rates calculated for the treatment of patients suffering HCV-2 infection were 92% (95% CI: 87% - 96%) using the SOF + RBV regimen for 12 weeks and 95% (95% CI: 85% - 100%) using the SOF + RBV + PegIFN regimen for 12 weeks. The pooled SVR calculated for the treatment of patients suffering HCV-3 infection was 55% (95% CI: 44% - 66%) using the SOF + RBV regimen for 12 weeks, 81% (95% CI: 72% - 88%) using the SOF + RBV regimen for 24 weeks, and 93% (95% CI: 85% - 99%) using the SOF + RBV + PegIFN regimen for 12 weeks. Conclusions: The combination of SOF and RBV with or without PegIFN for 12 weeks is highly efficacious (> 90%) for the treatment of patients with HCV-2 infection. However, for the treatment of patients with HCV-3 infection only 12 weeks of SOF + PegIFN + RBV would result in > 90% treatment success.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Bayatpoor, Mohammad Ehsan; Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran ; Baqiyatallah University of Medical Sciences, Tehran, Iran ; Meta-Analysis Study Group, Iran Hepatitis Network, Tehran, Iran ; Middle East Liver Disease (MELD) Center, Tehran, Iran

Khosravi, Mohammad Hossein ; Université de Liège - ULiège > Faculté de Médecine > Doct. sc. méd. (paysage)

Sharafi, Heidar; Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran ; Meta-Analysis Study Group, Iran Hepatitis Network, Tehran, Iran ; Middle East Liver Disease (MELD) Center, Tehran, Iran

Rezaee-Zavareh, Mohammad Saeid; Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran ; Baqiyatallah University of Medical Sciences, Tehran, Iran ; Meta-Analysis Study Group, Iran Hepatitis Network, Tehran, Iran ; Middle East Liver Disease (MELD) Center, Tehran, Iran

Behnava, Bita; Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran ; Meta-Analysis Study Group, Iran Hepatitis Network, Tehran, Iran ; Middle East Liver Disease (MELD) Center, Tehran, Iran

Alavian, Seyed Moayed; Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran ; Meta-Analysis Study Group, Iran Hepatitis Network, Tehran, Iran ; Middle East Liver Disease (MELD) Center, Tehran, Iran

Language :

English

Title :

Sofosbuvir and ribavirin with or without pegylated-interferon in hepatitis C virus genotype-2 or -3 infections: A systematic review and meta-analysis

Publication date :

February 2019

Journal title :

Archives of Clinical Infectious Diseases

eISSN :

2345-2641

Publisher :

Kowsar Medical Institute

Volume :

Issue :

Peer reviewed :

Peer reviewed

Additional URL :

https://sites.kowsarpub.com/archcid/articles/79465.html

Available on ORBi :

since 21 May 2022

Statistics

Number of views

40 (0 by ULiège)

Number of downloads

19 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of agespecific antibody to HCV seroprevalence. Hepatology. 2013;57(4): 1333-42. doi: 10.1002/hep.26141.
Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1): 41-52. doi: 10.1056/NEJM200107053450107.
Edlin BR, Winkelstein ER. Can hepatitis C be eradicated in the United States? Antiviral Res. 2014;110: 79-93. doi: 10.1016/j.antiviral.2014.07.015.
Kamal-Yanni M. Hepatitis C drug affordability. Lancet Glob Health. 2015;3(2): e73-4. doi: 10.1016/S2214-109X(14)70365-1.
Tapper EB, Afdhal NH. Is 3 the new 1: Perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat. 2013;20(10): 669-77. doi: 10.1111/jvh.12168.
Adinolfi LE, Guerrera B. All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. World J Hepatol. 2015;7(22): 2363-8. doi: 10.4254/wjh.v7.i22.2363.
Haj-Sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F. Interferon-lambda polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol. 2015;21(29): 8935-42. doi: 10.3748/wjg.v21.i29.8935.
Keshvari M, Alavian SM, Behnava B, Pouryasin A, Craig JC, Sharafi H. Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to peg-interferon-alpha and ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. J Clin Lab Anal. 2017;31(4). doi: 10.1002/jcla.22063.
Behnava B, Sharafi H, Keshvari M, Pouryasin A, Mehrnoush L, Salimi S, et al. The role of polymorphisms near the IL28B gene on response to peg-interferon and ribavirin in thalassemic patients with hepatitis C. Hepat Mon. 2016;16(1). e32703. doi: 10.5812/hepatmon.32703.
Heidrich B, Wiegand SB, Buggisch P, Hinrichsen H, Link R, Moller B, et al. Treatment of naive patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: Relevance for the new era of DAA. PLoS One. 2014;9(10). e108751. doi: 10.1371/journal.pone.0108751.
Keshvari M, Alavian SM, Behnava B, Pouryasin A, Sharafi H. The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. J Res Med Sci. 2016;21: 72. doi: 10.4103/1735-1995.189678.
Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20): 1867-77. doi: 10.1056/NEJMoa1214854.
Kao JH, Chien RN, Chang TT, Peng CY, Hu TH, Lo GH, et al. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int. 2016;36(8): 1101-7. doi: 10.1111/liv.13082.
Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: An open-label, phase 3 trial. J Viral Hepat. 2014;21(11): 762-8. doi: 10.1111/jvh.12312.
Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009;151(4): 264-9. W64.
Higgins JPT. Cochrane handbook for systematic reviews of interventions version 5.0.2. The Cochrane Collaboration; 2008.
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The newcastle-ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute; 2019.
Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferonalfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149(6): 1462-70. doi: 10.1053/j.gastro.2015.07.043.
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21): 1993-2001. doi: 10.1056/NEJMoa1316145.
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T,Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitisCinfection. N Engl J Med. 2013;368(20): 1878-87. doi: 10.1056/NEJMoa1214853.
Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1): 34-44. doi: 10.1056/NEJMoa1208953.
Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015;61(3): 769-75. doi: 10.1002/hep.27567.
Ahn SH, Lim YS, Lee KS, Paik SW, Lee YJ, Jeong SH, et al. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatmentexperienced Korean patients chronically infected with genotype 2 hepatitis C virus. J Viral Hepat. 2016;23(5): 358-65. doi: 10.1111/jvh.12499.
Maasoumy B, Vermehren J, Welker MW, Bremer B, Perner D, Honer Zu Siederdissen C, et al. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J Hepatol. 2016;65(3): 473-82. doi: 10.1016/j.jhep.2016.04.006.
Steinebrunner N, Sprinzl MF, Zimmermann T, Worns MA, Zimmerer T, Galle PR, et al. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center “real-life” cohort. BMC Gastroenterol. 2015;15: 97. doi: 10.1186/s12876-015-0328-9.
Jayasekera CR, Perumpail RB, Chao DT, Pham EA, Aggarwal A, Wong RJ, et al. Task-shifting: An approach to decentralized hepatitis C treatment in medically underserved areas. Dig Dis Sci. 2015;60(12): 3552-7. doi: 10.1007/s10620-015-3911-6.
Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: Results of the real-world, clinical practice HCV-TARGET study. Gut. 2017;66(10): 1844-52. doi: 10.1136/gutjnl-2016-311609.
Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Clin Mol Hepatol. 2015;21(4): 358-64. doi: 10.3350/cmh.2015.21.4.358.
Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. veterans. Aliment Pharmacol Ther. 2015;42(5): 559-73. doi: 10.1111/apt.13300.
Tacke F, Gunther R, Buggisch P, Klinker H, Schober A, John C, et al. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver Int. 2017;37(2): 205-11. doi: 10.1111/liv.13206.
Weiss JJ, Bhatti L, Dieterich DT, Edlin BR, Fishbein DA, Goetz MB, et al. Hepatitis C patients’ self-reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther. 2008;28(3): 289-93.
Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, et al. Recommendations for the clinical management of hepatitis c in Iran: A consensus-based national guideline. Hepat Mon. 2016;16(8). e40959. doi: 10.5812/hepatmon.guideline.
Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next steps toward eradication of hepatitis C in the era of direct acting antivirals. Hepat Mon. 2016;16(4). e37089. doi: 10.5812/hepatmon. 37089.
Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, Sharafi H. Combination of ledipasvir and sofosbuvir for treatment of hepatitis C virus genotype 1 infection: Systematic review and meta-analysis. Ann Hepatol. 2017;16(2): 188-97. doi: 10.5604/16652681.1231562.
Merat S, Sharifi AH, Haj-Sheykholeslami A, Poustchi H, Fattahi B, Nateghi-Baygi A, et al. The Efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3. Hepat Mon. 2016;17(1). doi: 10.5812/hepatmon.44564.